RenovoRx (NASDAQ:RNXT – Get Free Report) had its price target increased by equities researchers at Ascendiant Capital Markets from $8.00 to $8.25 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.
RenovoRx Stock Up 5.2 %
NASDAQ RNXT opened at $1.13 on Thursday. The company has a market cap of $27.00 million, a price-to-earnings ratio of -1.56 and a beta of 0.98. RenovoRx has a 52 week low of $0.53 and a 52 week high of $2.35. The business has a 50 day moving average price of $1.13 and a 200-day moving average price of $1.24.
RenovoRx (NASDAQ:RNXT – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.10) EPS for the quarter.
Institutional Investors Weigh In On RenovoRx
RenovoRx Company Profile
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Recommended Stories
- Five stocks we like better than RenovoRx
- Are Penny Stocks a Good Fit for Your Portfolio?
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- How to invest in marijuana stocks in 7 stepsĀ
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.